Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 11/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.65 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4412485 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL18130708 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL16692242 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73103 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL73290 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL7612587 | 0.92 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL72753 | 0.88 | CHRM3 (0.78) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1233262 | 0.85 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1233260 | 0.85 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| SCHEMBL1234306 | 0.85 | CHRM3 (0.73) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 72 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016162878-A1 | AN ADVANTAGEOUS PROCESS FOR PREPARING 1-AZONIABICYCLO[2.2.2]OCTANE,3-[(HYDROXYDI-2-THIENYLACETYL)OXY]-1-(3¬PHENOXYPROPYL)-, BROMIDE, (3R)- AND ITS NOVEL CRYSTALLINE FORM-I | HARMAN FINOCHEM LIMITED (IN) | 2016-10-13 | — | — | WO | claimed |
| WO-2014140318-A1 | IMPROVED PROCESS FOR ACYL TRANSFER REACTIONS | K.H.S. PHARMA HOLDING GMBH (DE) | 2014-09-18 | — | — | WO | claimed |
| US-8044205-B2 | Process for manufacturing 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octane bromide | LABORATORIOS ALMIRALL, S.A. (ES) | 2011-10-25 | — | — | US | claimed |
| US-20090299042-A1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO[2.2.2]OCTANE BROMIDE | ALMIRALL, S.A. (ES) | 2009-12-03 | — | — | US | claimed |
| EP-2044067-B1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3- PHENOXYPROPYL)-1 -AZONIABICYCLO[2.2.2]OCTANE BROMIDE | ALMIRALL SA (ES) | 2009-11-18 | — | — | EP | claimed |
| EP-2044067-A1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3- PHENOXYPROPYL)-1 -AZONIABICYCLO[2.2.2]OCTANE BROMIDE | Laboratorios Almirall, S.A. (ES) | 2009-04-08 | — | — | EP | claimed |
| WO-2008009397-A1 | PROCESS FOR MANUFACTURING 3(R)-(2-HYDROXY-2,2-DITHIEN-2-YLACETOXY)-1-(3-PHENOXYPROPYL)-1-AZONIABICYCLO[2.2.2]OCTANE BROMIDE | LABORATORIOS ALMIRALL, S.A. (ES) | 2008-01-24 | — | — | WO | claimed |
| CN-108586450-B | Recrystallization purification method of choline M receptor anticaking agent | 上海方予健康医药科技有限公司 | 2021-02-19 | — | — | CN | disclosed |
| US-20200405700-A1 | INHALABLE FORMULATION OF A SOLUTION CONTAINING FORMOTEROL FUMARATE AND ACLIDINIUM BROMIDE | Huang, Cai Gu (US) | 2020-12-31 | — | — | US | disclosed |
| US-10590124-B2 | Process for the preparation of aclidinium bromide | Hovione Scienta Limited (IE) | 2020-03-17 | — | — | US | disclosed |
| US-10590124-B2 | Process for the preparation of aclidinium bromide | Hovione Scienta Limited (IE) | 2020-03-17 | — | — | US | disclosed |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | ALMIRALL, S.A. (ES) | 2020-03-17 | — | — | US | disclosed |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | ALMIRALL SA (ES) | 2019-06-20 | — | — | US | disclosed |
| US-20060106055-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-05-18 | — | — | US | disclosed |
| US-20060106056-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | ALMIRALL PRODESFARMA, S.A. (ES) | 2006-05-18 | — | — | US | disclosed |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | ALMIRALL PRODESFARMA, S.A. (ES) | 2005-09-22 | — | — | US | disclosed |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-07-08 | — | — | US | disclosed |
| US-6750226-B2 | FOR MANUFACTURE OF MEDICAMENT FOR USE IN THERAPY OF RESPIRATORY, URINARY OR GASTROINTESTINAL DISEASE | ALMIRALL-PRODESFARMA, S.A. (ES) | 2004-06-15 | — | — | US | disclosed |
| EP-1200431-B1 | QUINUCLIDINE DERIVATIVES AND THEIR USE AS MUSCARINIC M3 RECEPTORS LIGANDS | ALMIRALL PRODESFARMA AG (CH) | 2003-03-26 | — | — | EP | disclosed |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | ALMIRALL, S.A. (ES) | 2003-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405700-A1 | INHALABLE FORMULATION OF A SOLUTION CONTAINING FORMOTEROL FUMARATE AND ACLIDINIUM BROMIDE | PEF1, CFTR, ACLY | CHRM3 13/4885CHRM2 34/4885CHRM1 139/4885 |
| US-10590124-B2 | Process for the preparation of aclidinium bromide | ACMSD, CHRND, ADRA2B | CHRM3 119/4885CHRM2 34/4885CHRM1 230/4885 |
| US-20060106056-A1 | 3(R)-1-Phenethyl-(9[H]-xanthene-9-carbonyloxy)-1-azoniabicyclo[2.2.2] octane quaternary salt with a mono- or polyvalent anion; antimuscarinic agents used to treat chronic obstructive pulmonary disease, chronic bronchitis, bronchial hyperreactivity, asthma, or rhinitis | CHRM3, CHRM4, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 5/4885 |
| US-20040132768-A1 | substituted with (hetero)aryl carbonyloxy group and quaternized, e.g., 3(R)-Diphenylacetoxy-1-(3-phenoxy-propyl)-1-azoniabicyclo[2.2.2]octane; bromide; antimuscarinic agents for treating COPD, chronic bronchitis, asthma and rhinitis. | CHRM3, CBR1, CHRNB1 | CHRM3 1/4885CHRM2 5/4885CHRM1 10/4885 |
| US-20050209272-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | NR3C2, NR3C1, NR4A3 | CHRM3 9/4885CHRM2 30/4885CHRM1 64/4885 |
| US-20190183867-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | CHRM3, CHRNB1, ARRB1 | CHRM3 1/4885CHRM2 4/4885CHRM1 5/4885 |
| US-20030055080-A1 | For manufacture of medicament for use in therapy of respiratory, urinary or gastrointestinal disease | NR1H4, CHRM3, CHRM4 | CHRM3 2/4885CHRM2 8/4885CHRM1 11/4885 |
| US-10588895-B2 | Quinuclidine derivatives and medicinal compositions containing the same | CHRM3, QDPR, CHRM2 | CHRM3 1/4885CHRM2 3/4885CHRM1 8/4885 |
| US-20060106055-A1 | 3(R)-(2-hydroxy-2,2-dithien-2-ylacetoxy)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2] octane in salt form, particularly bromide or trifluoroacetate, for treatment of respiratory disorders, alone or in combination with other bronchodilatory compounds | NR3C2, NR3C1, NR4A3 | CHRM3 7/4885CHRM2 23/4885CHRM1 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.